You are here

orphan drugs

AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer

AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer

Pharmaceutical Business Review

small cell lung cancer

Flag link:

Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD

Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD

Pharmaceutical Business Review

Reata Pharmaceuticals

autosomal dominant polycystic kidney disease

Flag link:

Orphan drugs market to soar to $224bn by 2024

Orphan drugs market to soar to $224bn by 2024

PM Live

Evaluate Pharma

Flag link:

Orphan Drug Designation Requests and Designations Dipped in 2018, But Orphan Approvals Are Up Again!

Orphan Drug Designation Requests and Designations Dipped in 2018, But Orphan Approvals Are Up Again!

FDA Law Blog

Flag link:

Report: Evaluating the Cost-Effectiveness and Controversies of Orphan Drugs

Report: Evaluating the Cost-Effectiveness and Controversies of Orphan Drugs

BioSpace

Orphan Drug Act

Flag link:

Clinical Costs for Orphan Drugs Lower Than Non-Orphan Drugs, Study Finds

Clinical Costs for Orphan Drugs Lower Than Non-Orphan Drugs, Study Finds

RAPS.org

Flag link:

New Industry Report Finds Most Orphan Drugs Aren't Successful

New Industry Report Finds Most Orphan Drugs Aren't Successful

BioSpace

Flag link:

FDA Faulted For Lapses In Orphan Drug Program

FDA Faulted For Lapses In Orphan Drug Program

NPR

Flag link:

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Yahoo/Zacks.com

eosinophilic granulomatosis with polyangiitis

Flag link:

Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

CP Wire

Array Biopharma

neurofibromatosis

Flag link:

FDA Finalizes Guidance Closing Pediatric Study Loophole

FDA Finalizes Guidance Closing Pediatric Study Loophole

RAPS.org

Flag link:

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

CP Wire

Flag link:

Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer

Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer

CP Wire

Seattle Genetics

clinical trials

HER2-positive metastatic breast cancer

Flag link:

Tetra Discovery Partners Initiates Ph II Trial of Fragile X Syndrome Drug

Tetra Discovery Partners Initiates Ph II Trial of Fragile X Syndrome Drug

CP Wire

Tetra Discovery Partners

Fragile X syndrome

clinical trials

Flag link:

Eagle Receives Orphan Drug Designation for Bendeka

Eagle Receives Orphan Drug Designation for Bendeka

CP Wire

Eagle Pharmaceuticals

Flag link:

Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Forbes

Flag link:

5 Best-Selling Orphan Drugs in the U.S.

5 Best-Selling Orphan Drugs in the U.S.

Motley Fool

Teva Pharmaceutical

Bristol-Myers Squibb

Flag link:

Half of orphan drug sales to come from cancer, Evaluate finds

Half of orphan drug sales to come from cancer, Evaluate finds

Biopharma Dive

Flag link:

Orphan drugs to grow twice as fast as rest of the industry: report

Orphan drugs to grow twice as fast as rest of the industry: report

Medical Marketing and Media

Flag link:

Market Exclusivity is not What Attracts Orphan Drug Investment, Research Finds

Market Exclusivity is not What Attracts Orphan Drug Investment, Research Finds

RAPS.org

market exclusivity

Flag link:

Pages